Description

Salofalk (mesalazine) Gastroresistant Granules 1.5 g. №35

Ingredients

Active ingredient: Mesalazine. Each sachet contains 1.5 g of mesalazine.

Dosage

Dosage: The usual dose is 1.5 g once daily, or as directed by a healthcare professional. The granules should be taken with or after food.

Indications

Indicated for: Treatment of mild to moderate ulcerative colitis and maintenance of remission.

Contraindications

Do not use if: Hypersensitive to mesalazine or any component of the formulation. Consult a doctor before use.

Directions

Directions for use: Dissolve the granules in water before taking. Do not crush or chew the granules. Follow the instructions provided by your healthcare provider.

Scientific Evidence

Mesalazine is a first-line treatment for ulcerative colitis due to its anti-inflammatory properties. It acts topically on the colonic mucosa, reducing the production of inflammatory mediators.

Studies have shown that mesalazine is effective in inducing and maintaining remission in ulcerative colitis. Research by Sandborn et al. (2003) demonstrated the efficacy of mesalazine in reducing disease activity and improving quality of life in patients with ulcerative colitis.

Additional Information

Mesalazine granules are gastroresistant, ensuring that the active ingredient is released in the colon for targeted treatment. This formulation minimizes systemic absorption, reducing the risk of systemic side effects.

Clinical trials have shown that mesalazine is well-tolerated with a favorable safety profile. It is considered a cornerstone in the management of ulcerative colitis, providing symptomatic relief and improving long-term outcomes for patients.